Maria Jose Herrero Mata

Maria Jose Herrero Mata

Auto-generated profile, based on publicly available information

Maria Jose Herrero Mata

Transfusional Medicine Group Vall d'Hebron Research Institute, Universitat Autònoma de Barcelona (VHIR‐UAB) Barcelona Spain

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

10 September 2026 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
MCMaria Francesca Cortese
Maria Francesca Cortese
APAdriana Palom
Adriana Palom
ASAriadna Rando Segura
Ariadna Rando Segura
FRFrancesc Rudilla
Francesc Rudilla
EREmma Enrich Rande
Emma Enrich Rande
MBMaria Buti
Maria Buti
Background: Hepatitis delta virus (HDV) infection causes the most severe form of viral hepatitis, with highly heterogeneous outcomes ranging from viral control to persistent viraemia and progressive liver disease. The Human Leukocyte Antigen (HLA) system plays a central role in antiviral immunity, yet its contribution to HDV disease remains poorly defined. We aimed to identify HLA genetic polymorphisms associated with virological control and disease severity. Methods: High‐resolution genotyping of classical (A, B, C, DPB1, DQB1, DRB1) and non‐classical (E, G) HLA was performed in 72 anti‐HDV‐positive patients. A group of healthy donors ( N = 150) was used as a reference. Patients were stratified by longitudinal HDV RNA status into viraemic (persistent viraemia, N = 36) and non‐viraemic (undetectable viraemia, N = 36) groups. Clinical data, including liver fibrosis stage, were collected. T cell receptor (TCR) β‐chain sequencing was performed in isolated CD3 + T cells from viraemic patients and compared to a group of healthy donors (HD; N = 44). Results: The HLA‐A*11:01 allele was exclusively observed in viraemic patients ( p ‐value < 0.001, FDR = 0.02; allele frequency = 0.15). Multivariate analysis confirmed its independent association with persistent viraemia and advanced fibrosis. Notably, its frequency did not differ between our cohort and the overall reference population. Furthermore, viraemic HLA‐A*11:01 carriers exhibited significantly higher TCRβ chain clonality, consistent with a restricted and potentially ineffective antiviral T‐cell response. Conclusion: HLA‐A*11:01 identifies a subgroup of HDV patients at high risk of persistent viral replication and advanced fibrosis. The integration of HLA genotyping into risk stratification algorithms may help to early identify patients requiring intensified monitoring and timely therapeutic intervention.